Argenx Agrees to Buy Forte Biosciences for $2.2 Billion, 41% Premium
businessmergers-acquisitions 3 posts · 3 accounts
Argenx has agreed to acquire all shares of Forte Biosciences in an all-cash deal valued at approximately $2.2 billion.
The transaction carries a 41% premium to the Nasdaq-listed company’s closing price on Friday and expands Argenx’s portfolio of immunology medicines.
From the sources (3 posts)
@businessArgenx agreed to buy Forte Biosciences for about $2.2 billion in cash to expand its portfolio of immunology medicines.
@wsjThe deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
@reutersArgenx to buy Forte Biosciences for about $2.2 billion